{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:20:13Z","timestamp":1787988013946,"version":"build-2784847793"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"South Metropolitan Health Service"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Lu-PSMA is an effective therapy for mCRPC. Capecitabine is an established radiosensitiser in several solid tumours and may enhance therapeutic response when combined with radioligand therapy. We evaluated the safety and maximum tolerated dose (MTD) of capecitabine with Lu-PSMA in a heavily pre-treated mCRPC cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Men with mCRPC previously treated with \u2265\u20091 taxane and \u2265\u20091 androgen receptor pathway inhibitor, and deemed suitable for Lu-PSMA on PSMA-PET, were enrolled in a 3\u2009+\u20093 dose-escalation study. Capecitabine was administered at four dose levels (275 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      \u2013 1000 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) on days 1\u201314, with Lu-PSMA on day 10 of a 42-day cycle, for up to six cycles. The primary endpoint was the MTD; secondary endpoints included safety, PSA-50 and objective response rates (RR), PSA-progression free survival (PFS), clinical and radiological PFS, and overall survival (OS). PSA was assessed every two weeks; imaging every 12 weeks.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      12 patients received at least one dose of Lu-PSMA. Median age was 75. No dose-limiting toxicities occurred, establishing the MTD at 1000 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      . Common treatment-related adverse events were nausea, fatigue, and diarrhoea. Across dose levels, the PSA-50 RR was 50%, and PSA-PFS was 4.7 months (95% CI 2.3\u201321.6). One patient with measurable disease achieved a partial response. Exploratory PSMA PET biomarker analyses were negative, likely limited by small sample size.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Capecitabine 1000 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      in combination with Lu-PSMA is safe and tolerable in heavily pre\u2011treated mCRPC. A dose\u2011expansion cohort is ongoing to further evaluate efficacy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-08006-x","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T01:37:51Z","timestamp":1781833071000},"page":"6452-6460","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lutetium-177-PSMA I&amp;T (Lu-PSMA) with radiosensitising capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC): results of phase Ia study"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0981-7017","authenticated-orcid":false,"given":"Claudia","family":"Leslie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyad","family":"Al-Ogaili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leone","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Slattery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Shaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Marsavela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alana","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"8006_CR1","unstructured":"AIHW. Cancer data in Australia 2024 [updated 09 Dec 2024]. Available from: https:\/\/www.aihw.gov.au\/reports\/cancer\/cancer-data-in-australia\/contents\/overview"},{"issue":"1","key":"8006_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2019;381(1):13\u201324.","journal-title":"N Engl J Med"},{"issue":"2","key":"8006_CR3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med. 2019;381(2):121\u201331.","journal-title":"N Engl J Med"},{"issue":"32","key":"8006_CR4","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2019;37(32):2974\u201386.","journal-title":"J Clin Oncol"},{"issue":"3","key":"8006_CR5","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/ijc.34018","volume":"151","author":"ND James","year":"2022","unstructured":"James ND, Clarke NW, Cook A, Ali A, Hoyle AP, Attard G, et al. Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). Int J Cancer. 2022;151(3):422\u201334.","journal-title":"Int J Cancer"},{"issue":"5","key":"8006_CR6","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20(5):686\u2013700.","journal-title":"Lancet Oncol"},{"issue":"10336","key":"8006_CR7","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fl\u00e9chon A, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design. Lancet. 2022;399(10336):1695\u2013707.","journal-title":"Lancet"},{"issue":"12","key":"8006_CR8","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022;386(12):1132\u201342.","journal-title":"N Engl J Med"},{"issue":"11","key":"8006_CR9","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.2967\/jnumed.115.161299","volume":"56","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, et al. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET\/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions. J Nucl Med. 2015;56(11):1697\u2013705.","journal-title":"J Nucl Med"},{"issue":"8","key":"8006_CR10","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1021\/cr500171e","volume":"115","author":"S Banerjee","year":"2015","unstructured":"Banerjee S, Pillai MR, Knapp FF. Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications. Chem Rev. 2015;115(8):2934\u201374.","journal-title":"Chem Rev"},{"issue":"12","key":"8006_CR11","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091\u2013103.","journal-title":"N Engl J Med"},{"issue":"1091","key":"8006_CR12","doi-asserted-by":"publisher","first-page":"20180108","DOI":"10.1259\/bjr.20180108","volume":"91","author":"D Pencharz","year":"2018","unstructured":"Pencharz D, Gnanasegaran G, Navalkissoor S. Theranostics in neuroendocrine tumours: somatostatin receptor imaging and therapy. Br J Radiol. 2018;91(1091):20180108.","journal-title":"Br J Radiol"},{"issue":"10446","key":"8006_CR13","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, et al. [(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high\u2013dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403(10446):2807\u201317.","journal-title":"Lancet"},{"issue":"2","key":"8006_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376(2):125\u201335.","journal-title":"N Engl J Med"},{"issue":"2","key":"8006_CR15","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s00259-010-1631-x","volume":"38","author":"PG Claringbold","year":"2011","unstructured":"Claringbold PG, Brayshaw PA, Price RA, Turner JH. Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2011;38(2):302\u201311.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8006_CR16","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1200\/GO.21.00103","volume":"7","author":"S Satapathy","year":"2021","unstructured":"Satapathy S, Mittal BR, Sood A, Sood A, Kapoor R, Gupta R, et al. (177)Lu-DOTATATE Plus Radiosensitizing Capecitabine Versus Octreotide Long-Acting Release as First-Line Systemic Therapy in Advanced Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors: A Single-Institution Experience. JCO Glob Oncol. 2021;7:1167\u201375.","journal-title":"JCO Glob Oncol"},{"issue":"11","key":"8006_CR17","doi-asserted-by":"publisher","first-page":"e457","DOI":"10.1097\/RLU.0000000000001816","volume":"42","author":"S Ballal","year":"2017","unstructured":"Ballal S, Yadav MP, Damle NA, Sahoo RK, Bal C. Concomitant 177Lu-DOTATATE and Capecitabine Therapy in Patients With Advanced Neuroendocrine Tumors: A Long-term-Outcome, Toxicity, Survival, and Quality-of-Life Study. Clin Nucl Med. 2017;42(11):e457\u201366.","journal-title":"Clin Nucl Med"},{"issue":"4","key":"8006_CR18","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/sj.pcan.4500821","volume":"8","author":"J Spicer","year":"2005","unstructured":"Spicer J, Plunkett T, Somaiah N, Chan S, Kendall A, Bolunwu N, Pandha H. Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer. \tProstate Cancer Prostatic Dis. 2005;8(4):364\u20138.","journal-title":"Prostate Cancer and Prostatic Diseases"},{"issue":"3","key":"8006_CR19","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s13139-021-00696-5","volume":"55","author":"M Maharaj","year":"2021","unstructured":"Maharaj M, Heslop L, Govender T, Korowlay N, Singh A, Choudhary P, et al. The Outcome and Safety of Re-challenge Lutetium-177 PSMA ((177)Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer-a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report. Nucl Med Mol Imaging. 2021;55(3):136\u201340.","journal-title":"Nucl Med Mol Imaging"},{"issue":"4","key":"8006_CR20","doi-asserted-by":"publisher","first-page":"560","DOI":"10.2967\/jnumed.121.262552","volume":"63","author":"S Pathmanandavel","year":"2022","unstructured":"Pathmanandavel S, Crumbaker M, Yam AO, Nguyen A, Rofe C, Hovey E, et al. (177)Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I\/II Trial. J Nucl Med. 2022;63(4):560\u20136.","journal-title":"J Nucl Med"},{"issue":"5","key":"8006_CR21","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/bju.15491","volume":"128","author":"L Emmett","year":"2021","unstructured":"Emmett L, Subramaniam S, Joshua AM, Crumbaker M, Martin A, Zhang AY, et al. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). BJU Int. 2021;128(5):642\u201351.","journal-title":"BJU Int"},{"issue":"4","key":"8006_CR22","doi-asserted-by":"publisher","first-page":"572","DOI":"10.2967\/jnumed.124.269252","volume":"66","author":"L Kostos","year":"2025","unstructured":"Kostos L, Buteau JP, Kong G, Tran B, Haskali MB, Fahey M, et al. Clinical Trial Protocol for LuCAB: A Phase I-II Trial Evaluating Cabazitaxel in Combination with [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2025;66(4):572\u20138.","journal-title":"J Nucl Med"},{"key":"8006_CR23","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1200\/JCO.2023.41.16_suppl.5005","volume":"41","author":"AM Joshua","year":"2023","unstructured":"Joshua AM, Emmett L, Crumbaker M, Bressel M, Huynh R, Banks PD, et al. Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol. 2023;41:5005.","journal-title":"J Clin Oncol"},{"key":"8006_CR24","doi-asserted-by":"publisher","first-page":"5017","DOI":"10.1200\/JCO.2022.40.16_suppl.5017","volume":"40","author":"S Sandhu","year":"2022","unstructured":"Sandhu S, Joshua AM, Emmett L, Spain LA, Horvath L, Crumbaker M, et al. PRINCE: Phase 1 trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2022;40:5017.","journal-title":"J Clin Oncol"},{"key":"8006_CR25","doi-asserted-by":"publisher","first-page":"5016","DOI":"10.1200\/JCO.2025.43.16_suppl.5016","volume":"43","author":"S Sandhu","year":"2025","unstructured":"Sandhu S, Subramaniam S, Thomas H, Tan TH, Goh JC, Dhiantrava N, et al. 177Lu-PSMA-617 with ipilimumab (ipi) and nivolumab (nivo) in metastation castration-resistant prostate cancer (mCRPC): An investigator-initiated phase 2 trial (EVOLUTION; ANZUP2001). J Clin Oncol. 2025;43:5016.","journal-title":"J Clin Oncol"},{"issue":"12","key":"8006_CR26","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34(12):1402\u201318.","journal-title":"J Clin Oncol"},{"issue":"9","key":"8006_CR27","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1007\/s00259-022-05744-6","volume":"49","author":"PE Hartrampf","year":"2022","unstructured":"Hartrampf PE, Weinzierl FX, Buck AK, Rowe SP, Higuchi T, Seitz AK, et al. Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2022;49(9):3269\u201376.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"8006_CR28","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"10276","key":"8006_CR29","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797\u2013804.","journal-title":"Lancet"},{"issue":"6","key":"8006_CR30","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","volume":"19","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19(6):825\u201333.","journal-title":"Lancet Oncol"},{"issue":"5","key":"8006_CR31","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","volume":"25","author":"L Emmett","year":"2024","unstructured":"Emmett L, Subramaniam S, Crumbaker M, Nguyen A, Joshua AM, Weickhardt A, et al. [(177)Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2024;25(5):563\u201371.","journal-title":"Lancet Oncol"},{"key":"8006_CR32","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1200\/JCO.2023.41.16_suppl.5005","volume":"41","author":"S Sandhu","year":"2023","unstructured":"Sandhu S, Joshua AM, Emmett L, Crumbaker M, Bressel M, Huynh R, et al. LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol. 2023;41:5005.","journal-title":"J Clin Oncol"},{"issue":"6","key":"8006_CR33","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S1470-2045(12)70116-X","volume":"13","author":"RD Hofheinz","year":"2012","unstructured":"Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012;13(6):579\u201388.","journal-title":"Lancet Oncol"},{"issue":"4","key":"8006_CR34","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1470-2045(13)70021-4","volume":"14","author":"S Mukherjee","year":"2013","unstructured":"Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol. 2013;14(4):317\u201326.","journal-title":"Lancet Oncol"},{"issue":"2","key":"8006_CR35","doi-asserted-by":"publisher","first-page":"e233460","DOI":"10.1148\/radiol.233460","volume":"312","author":"PH Kuo","year":"2024","unstructured":"Kuo PH, Morris MJ, Hesterman J, Kendi AT, Rahbar K, Wei XX, et al. Quantitative (68)Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following (177)Lu-PSMA-617 (VISION Trial). Radiology. 2024;312(2):e233460.","journal-title":"Radiology"},{"issue":"11","key":"8006_CR36","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","volume":"23","author":"JP Buteau","year":"2022","unstructured":"Buteau JP, Martin AJ, Emmett L, Iravani A, Sandhu S, Joshua AM, et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given 177Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol. 2022;23(11):1389\u201397.","journal-title":"Lancet Oncol"},{"issue":"6","key":"8006_CR37","doi-asserted-by":"publisher","first-page":"833","DOI":"10.2967\/jnumed.124.268818","volume":"66","author":"V Murthy","year":"2025","unstructured":"Murthy V, Ludwig V, Gafita A, Hope TA, Calais J. The Role of PSMA PET Parameters as Biomarkers for Response to PSMA-Targeted Radiopharmaceutical Therapy. J Nucl Med. 2025;66(6):833\u20138.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08006-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08006-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08006-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:00:53Z","timestamp":1787986853000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08006-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["8006"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08006-x","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"4 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the South Metropolitan Health Service Human Research Ethics Committee (15\/3\/2023, RGS0000005919).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"order":4,"name":"Ethics","label":"Registered with the Australian New Zealand Clinical Trials Registry 6\/10\/2023","group":{"name":"EthicsHeading","label":"Declarations"}}]}}